{"Title": "The INNs and outs of antibody nonproprietary names", "Year": 2016, "Source": "mAbs", "Volume": "8", "Issue": 1, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 24, "DOI": "10.1080/19420862.2015.1114320", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84961642643&origin=inward", "Abstract": "\u00a9 2016, Tim D. Jones\u2026.A n important step in drug development is the assignment of an International Nonproprietary Name (INN) by the World Health Organization (WHO) that provides healthcare professionals with a unique and universally available designated name to identify each pharmaceutical substance. Monoclonal antibody INNs comprise a \u2013mab suffix preceded by a substem indicating the antibody type, e.g., chimeric (-xi-), humanized (-zu-), or human (-u-). The WHO publishes INN definitions that specify how new monoclonal antibody therapeutics are categorized and adapts the definitions to new technologies. However, rapid progress in antibody technologies has blurred the boundaries between existing antibody categories and created a burgeoning array of new antibody formats. Thus, revising the INN system for antibodies is akin to aiming for a rapidly moving target. The WHO recently revised INN definitions for antibodies now to be based on amino acid sequence identity. These new definitions, however, are critically flawed as they are ambiguous and go against decades of scientific literature. A key concern is the imposition of an arbitrary threshold for identity against human germline antibody variable region sequences. This leads to inconsistent classification of somatically mutated human antibodies, humanized antibodies as well as antibodies derived from semi-synthetic/synthetic libraries and transgenic animals. Such sequence-based classification implies clear functional distinction between categories (e.g., immunogenicity). However, there is no scientific evidence to support this. Dialog between the WHO INN Expert Group and key stakeholders is needed to develop a new INN system for antibodies and to avoid confusion and miscommunication between researchers and clinicians prescribing antibodies.", "AuthorKeywords": ["Antibody", "Chimeric", "Complementarity Determining Region (CDR)", "Definition", "Framework", "Humanized", "International Immunogenetics Information System (IMGT)", "International Nonproprietary Name (INN)", "Monoclonal", "World Health Organization (WHO)"], "IndexKeywords": ["Animals", "Antibodies", "Humans", "Terminology as Topic"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-84961642643", "SubjectAreas": [["Immunology and Allergy", "MEDI", "2723"], ["Immunology", "IMMU", "2403"]], "AuthorData": {"57198743696": {"Name": "Jones T.D.", "AuthorID": "57198743696", "AffiliationID": "60112902", "AffiliationName": "Antitope Ltd. (part of Abzena Plc.)"}, "14060338500": {"Name": "Holgate R.G.E.", "AuthorID": "14060338500", "AffiliationID": "60112902", "AffiliationName": "Antitope Ltd. (part of Abzena Plc.)"}, "7403074461": {"Name": "Baker M.P.", "AuthorID": "7403074461", "AffiliationID": "60112902", "AffiliationName": "Antitope Ltd. (part of Abzena Plc.)"}, "57205745802": {"Name": "Carter P.J.", "AuthorID": "57205745802", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "6603908403": {"Name": "H\u00f6tzel I.", "AuthorID": "6603908403", "AffiliationID": "60026209", "AffiliationName": "Genentech Inc."}, "7102515796": {"Name": "Pl\u00fcckthun A.", "AuthorID": "7102515796", "AffiliationID": "60012614", "AffiliationName": "Department of Biochemistry, University of Zurich"}, "57188985547": {"Name": "V\u00e1squez M.", "AuthorID": "57188985547", "AffiliationID": "112687527", "AffiliationName": "Adimab LLC."}, "7003946647": {"Name": "Popplewell A.G.", "AuthorID": "7003946647", "AffiliationID": "60068605", "AffiliationName": "UCB Pharma."}, "7004044140": {"Name": "Parren P.W.H.I.", "AuthorID": "7004044140", "AffiliationID": "60015618", "AffiliationName": "Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center"}, "6603349007": {"Name": "Rademaker H.J.", "AuthorID": "6603349007", "AffiliationID": "60105145", "AffiliationName": "Genmab"}, "6603102149": {"Name": "Enzelberger M.", "AuthorID": "6603102149", "AffiliationID": "60107784", "AffiliationName": "MorphoSys AG."}, "35458817900": {"Name": "Clark M.R.", "AuthorID": "35458817900", "AffiliationID": "116581401", "AffiliationName": "Clark Antibodies Ltd."}, "7402516730": {"Name": "Lowe D.C.", "AuthorID": "7402516730", "AffiliationID": "60005634, 60101501", "AffiliationName": "MedImmune Ltd."}, "6602940561": {"Name": "Dahiyat B.I.", "AuthorID": "6602940561", "AffiliationID": "60012255", "AffiliationName": "Xencor."}, "57193985542": {"Name": "Smith V.", "AuthorID": "57193985542", "AffiliationID": "60002909", "AffiliationName": "Gilead Sciences Inc."}, "24735788400": {"Name": "Lambert J.M.", "AuthorID": "24735788400", "AffiliationID": "60006003", "AffiliationName": "ImmunoGen Inc."}, "8611127900": {"Name": "Wu H.", "AuthorID": "8611127900", "AffiliationID": "60005634", "AffiliationName": "MedImmune."}, "57215568551": {"Name": "Reilly M.", "AuthorID": "57215568551", "AffiliationID": "112815728", "AffiliationName": "Opsona Therapeutics Ltd."}, "57217947752": {"Name": "Haurum J.S.", "AuthorID": "57217947752", "AffiliationID": "60117368", "AffiliationName": "F-Star Biotechnology Ltd."}, "35499053300": {"Name": "D\u00fcbel S.", "AuthorID": "35499053300", "AffiliationID": "60007902", "AffiliationName": "Technische Universit\u00e4t Braunschweig., Institute of Biochemistry, Biotechnology and Bioinformatics Spielmannstr. 7"}, "57214771038": {"Name": "Huston J.S.", "AuthorID": "57214771038", "AffiliationID": "116582492", "AffiliationName": "The Antibody Society and Huston Bio- Consulting LLC."}, "15925972700": {"Name": "Schirrmann T.", "AuthorID": "15925972700", "AffiliationID": "114497960", "AffiliationName": "Yumab GmbH."}, "57188974706": {"Name": "Janssen R.A.J.", "AuthorID": "57188974706", "AffiliationID": "60094287", "AffiliationName": "Galapagos NV."}, "6603299826": {"Name": "Steegmaier M.", "AuthorID": "6603299826", "AffiliationID": "60088421, 60072289", "AffiliationName": "Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Penzberg"}, "57188989811": {"Name": "Gross J.A.", "AuthorID": "57188989811", "AffiliationID": "60176010", "AffiliationName": "Emergent BioSolutions."}, "56734615300": {"Name": "Bradbury A.R.M.", "AuthorID": "56734615300", "AffiliationID": "60006164", "AffiliationName": "Biosciences Division., Los Alamos National Laboratory, MS-M888, TA-43, HRL-1"}, "7401577043": {"Name": "Burton D.R.", "AuthorID": "7401577043", "AffiliationID": "60007103", "AffiliationName": "The Scripps Research Institute."}, "7202564539": {"Name": "Dimitrov D.S.", "AuthorID": "7202564539", "AffiliationID": "60027053", "AffiliationName": "Protein Interactions Section., Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute"}, "7003689959": {"Name": "Chester K.A.", "AuthorID": "7003689959", "AffiliationID": "60109234", "AffiliationName": "UCL Cancer Institute."}, "7007135120": {"Name": "Glennie M.J.", "AuthorID": "7007135120", "AffiliationID": "60025287, 60021722", "AffiliationName": "Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital"}, "56389692100": {"Name": "Davies J.", "AuthorID": "56389692100", "AffiliationID": "60025685", "AffiliationName": "Lilly Biotechnology Center"}, "57202675396": {"Name": "Walker A.", "AuthorID": "57202675396", "AffiliationID": "60017488, 60020649", "AffiliationName": "GSK., Addenbrooke\u2019s Centre for Clinical Investigation, Addenbrooke\u2019s Hospital"}, "57212400075": {"Name": "Martin S.", "AuthorID": "57212400075", "AffiliationID": "60020649", "AffiliationName": "GSK, Medicines Research Centre"}, "7005010269": {"Name": "McCafferty J.", "AuthorID": "7005010269", "AffiliationID": "60111357", "AffiliationName": "Iontas Ltd."}}}